Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium

- Friends! This biopsy has a ticker symbol. Ginkgo Datapoints and Apheris are launching the Antibody Developability Consortium, a federated AI infrastructure for pharma giants like AbbVie and Takeda. They’re pooling proprietary sequences to train foundation models on manufacturability risks, keeping data private via PoD seals. It’s not just wet-lab work; it’s machine learning for biophysical stability. I treated cats. Same thing, only more honest—predicting failure before the clinical trial burns cash. By 2027, this standardized dataset should help select better candidates earlier, reducing development friction. No panic here, just efficient risk detection. That’s not panic, that’s a diagnostic dance. The hash manifest of health is being rewritten, one antibody at a time.